Lung transplantation, ex-vivo reconditioning and regeneration: State of the art and perspectives

Lorenzo Rosso, Alberto Zanella, Ilaria Righi, Mario Barilani, Lorenza Lazzari, Eleonora Scotti, Francesca Gori, Paolo Mendogni

Research output: Contribution to journalReview article

Abstract

Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.

Original languageEnglish
Pages (from-to)S2423-S2430
JournalJournal of Thoracic Disease
Volume10
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Lung Transplantation
Regeneration
Lung
Perfusion
Mesenchymal Stromal Cells
Transplantation
Transplants
Waiting Lists
Immunomodulation
Cell- and Tissue-Based Therapy
Mortality

Keywords

  • Cell- and tissue-based therapy
  • Lung transplantation
  • Perfusion
  • Tissue and organ procurement

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lung transplantation, ex-vivo reconditioning and regeneration : State of the art and perspectives. / Rosso, Lorenzo; Zanella, Alberto; Righi, Ilaria; Barilani, Mario; Lazzari, Lorenza; Scotti, Eleonora; Gori, Francesca; Mendogni, Paolo.

In: Journal of Thoracic Disease, Vol. 10, 01.07.2018, p. S2423-S2430.

Research output: Contribution to journalReview article

@article{582d9f8606024411aa7dbc6bf7083e3e,
title = "Lung transplantation, ex-vivo reconditioning and regeneration: State of the art and perspectives",
abstract = "Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.",
keywords = "Cell- and tissue-based therapy, Lung transplantation, Perfusion, Tissue and organ procurement",
author = "Lorenzo Rosso and Alberto Zanella and Ilaria Righi and Mario Barilani and Lorenza Lazzari and Eleonora Scotti and Francesca Gori and Paolo Mendogni",
year = "2018",
month = "7",
day = "1",
doi = "10.21037/jtd.2018.04.151",
language = "English",
volume = "10",
pages = "S2423--S2430",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Lung transplantation, ex-vivo reconditioning and regeneration

T2 - State of the art and perspectives

AU - Rosso, Lorenzo

AU - Zanella, Alberto

AU - Righi, Ilaria

AU - Barilani, Mario

AU - Lazzari, Lorenza

AU - Scotti, Eleonora

AU - Gori, Francesca

AU - Mendogni, Paolo

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.

AB - Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.

KW - Cell- and tissue-based therapy

KW - Lung transplantation

KW - Perfusion

KW - Tissue and organ procurement

UR - http://www.scopus.com/inward/record.url?scp=85050657371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050657371&partnerID=8YFLogxK

U2 - 10.21037/jtd.2018.04.151

DO - 10.21037/jtd.2018.04.151

M3 - Review article

AN - SCOPUS:85050657371

VL - 10

SP - S2423-S2430

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

ER -